Mymetics Corporation Share Price

MYMX

US62856A3005

Biotechnology & Medical Research

Delayed OTC Markets 17:02:13 11/05/2026 BST			5-day change	1st Jan Change
0.000300 ^USD	-.--%		-.--%	-

20/11/23	Mymetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
18/08/23	Mymetics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

Valuation: Mymetics Corporation

Market Cap	439K 389K 364K 330K 624K 42.3M 628K 4.38M 1.7M 21.58M 1.65M 1.61M 69.37M	P/E 2021	-1.86x	P/E 2022	-1.77x
Enterprise Value	72.12M 64.02M 59.91M 54.31M 103M 6.95B 103M 720M 280M 3.55B 271M 265M 11.4B	EV / Sales 2021	177x	EV / Sales 2022	78x
Free-Float	99.88%	Yield 2021 *	-	Yield 2022	-

* Estimated data More valuation ratios

Latest news: Mymetics Corporation

20/11/23	Mymetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
18/08/23	Mymetics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
15/05/23	Mymetics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
11/04/23	Mymetics Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	CI
10/04/23	Mymetics Corporation Auditor Raises 'Going Concern' Doubt	CI
17/01/23	Mymetics Corporation Appoints Marcel B. Rüegg to the Board	CI
28/12/22	Mymetics Corporation Announces Resignation of Ernest M. Stern as A Member of the Board of Directors	CI
14/11/22	Mymetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
11/08/22	Mymetics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI
13/05/22	Mymetics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
31/03/22	Mymetics Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	CI
30/03/22	Mymetics Corporation Auditor Raises 'Going Concern' Doubt	CI
12/11/21	Mymetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	CI

More news

Press Releases: Mymetics Corporation

11/04/23	MYMETICS CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
27/02/23	MYMETICS CORP : Other Events (form 8-K)	AQ
08/02/23	MYMETICS CORP : Other Events (form 8-K)	AQ
17/01/23	MYMETICS CORP : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
28/12/22	MYMETICS CORP : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ

More press releases

Managers and Directors: Mymetics Corporation

Manager	Title	Age	Since
Ronald Hugo Gerard Kempers CEO	Chief Executive Officer	58	18/11/2012

More insiders

Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.

Employees

Sector

Biotechnology & Medical Research

More about the company

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

Stock Market
Stocks
MYMX Stock

The best tools reserved for subscribers to boost the performance of your investments!

Current year	0		0
1 year	0		0
3 years	0		5.6
5 years	0		230
10 years	0		380

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MYMETICS CORPORATION	-.--%	-.--%	-.--%	-99.99%	45
WUXI APPTEC CO., LTD.	+4.16%	+3.42%	+49.37%	+94.17%	74.31B
ARGENX SE	+2.76%	-1.60%	+22.80%	+78.53%	56.95B
LONZA GROUP AG	+0.24%	-1.34%	+3.41%	+34.31%	48.3B
REVOLUTION MEDICINES, INC.	-4.52%	-3.15%	+325.18%	+690.93%	44.51B
IQVIA HOLDINGS INC.	-1.13%	-2.11%	+28.43%	+32.56%	43.8B
BEONE MEDICINES AG	+1.06%	-0.30%	+5.70%	+109.44%	41.12B
CELLTRION, INC.	-0.11%	+2.30%	+9.19%	+58.68%	31.07B
WUXI BIOLOGICS (CAYMAN) INC.	+4.51%	+8.43%	+37.27%	+34.97%	28.97B
BIONTECH SE	-1.39%	-2.36%	-8.48%	-13.46%	24.53B
Average	+0.51%	-0.18%	+47.29%	+102.01%	39.36B
Weighted average by Cap.	+0.88%	-0.50%	+56.52%	+132.93%

	2021	2022
Net sales	430K 382K 357K 324K 611K 41.45M 616K 4.29M 1.67M 21.15M 1.61M 1.58M 67.98M	1.03M 913K 854K 774K 1.46M 99.1M 1.47M 10.26M 3.99M 50.55M 3.86M 3.78M 163M
Net income	-4.73M -4.2M -3.93M -3.56M -6.73M -456M -6.77M -47.19M -18.36M -233M -17.75M -17.37M -748M	-4.8M -4.27M -3.99M -3.62M -6.83M -463M -6.88M -47.94M -18.65M -236M -18.04M -17.65M -760M
Net Debt	67.1M 59.56M 55.74M 50.52M 95.42M 6.47B 96.11M 669M 260M 3.3B 252M 246M 10.61B	71.68M 63.63M 59.55M 53.98M 102M 6.91B 103M 715M 278M 3.53B 269M 263M 11.33B

Mymetics Corporation Share Price

Stocks

MYMX

US62856A3005

Biotechnology & Medical Research

Valuation: Mymetics Corporation

Chart: Mymetics Corporation

Latest news: Mymetics Corporation

Press Releases: Mymetics Corporation

Price Extremes

Managers and Directors: Mymetics Corporation

Bio Therapeutic Drugs

Financials

Company Profile